The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Prabhat K Singh - One of the best experts on this subject based on the ideXlab platform.

  • an evaluation of the efficacy of aspirin and Benzydamine hydrochloride gargle for attenuating postoperative sore throat a prospective randomized single blind study
    Anesthesia & Analgesia, 2006
    Co-Authors: Anil Agarwal, Debolina Goswami, Sanjay Dhiraaj, Sukhendu Nath, Devendra Gupta, Prabhat K Singh
    Abstract:

    Postoperative sore throat (POST), although a minor complication, remains a source of postoperative morbidity. We compared the efficacy of dispersible aspirin gargle to Benzydamine hydrochloride (a topical nonsteroidal anti inflammatory drug) gargles for prevention of POST. We enrolled 60 consecutive

  • an evaluation of the efficacy of aspirin and Benzydamine hydrochloride gargle for attenuating postoperative sore throat a prospective randomized single blind study
    Anesthesia & Analgesia, 2006
    Co-Authors: Anil Agarwal, Debolina Goswami, Sanjay Dhiraaj, Sukhendu Nath, Devendra Gupta, Prabhat K Singh
    Abstract:

    Postoperative sore throat (POST), although a minor complication, remains a source of postoperative morbidity. We compared the efficacy of dispersible aspirin gargle to Benzydamine hydrochloride (a topical nonsteroidal anti inflammatory drug) gargles for prevention of POST. We enrolled 60 consecutive female patients, 16-60 yr of age, ASA physical status I or II, undergoing elective modified radical mastectomy under general anesthesia in this prospective, randomized, placebo-controlled, single-blind study. Patients were randomly divided into 3 groups of 20 subjects each: Group 1 (C) mineral water; Group 2 (AS) tab aspirin 350 mg; and Group 3 (BH) 15 mL of Benzydamine hydrochloride (0.15%). All the medications were made into 30 mL of solution. Patients were asked to gargle this mixture for 30 s, 5 min before induction of anesthesia. Grading of POST was done at 0, 2, 4, and 24 h postoperatively on a 4-point scale (0-3). Aspirin gargles reduced the incidence of POST for 4 h whereas Benzydamine hydrochloride gargles reduced POST for 24 h. POST was more severe in the control group at 0 and 2 h (P < 0.05). Aspirin and Benzydamine hydrochloride gargles significantly reduced the incidence and severity of POST (P < 0.05).

Anil Agarwal - One of the best experts on this subject based on the ideXlab platform.

  • an evaluation of the efficacy of aspirin and Benzydamine hydrochloride gargle for attenuating postoperative sore throat a prospective randomized single blind study
    Anesthesia & Analgesia, 2006
    Co-Authors: Anil Agarwal, Debolina Goswami, Sanjay Dhiraaj, Sukhendu Nath, Devendra Gupta, Prabhat K Singh
    Abstract:

    Postoperative sore throat (POST), although a minor complication, remains a source of postoperative morbidity. We compared the efficacy of dispersible aspirin gargle to Benzydamine hydrochloride (a topical nonsteroidal anti inflammatory drug) gargles for prevention of POST. We enrolled 60 consecutive

  • an evaluation of the efficacy of aspirin and Benzydamine hydrochloride gargle for attenuating postoperative sore throat a prospective randomized single blind study
    Anesthesia & Analgesia, 2006
    Co-Authors: Anil Agarwal, Debolina Goswami, Sanjay Dhiraaj, Sukhendu Nath, Devendra Gupta, Prabhat K Singh
    Abstract:

    Postoperative sore throat (POST), although a minor complication, remains a source of postoperative morbidity. We compared the efficacy of dispersible aspirin gargle to Benzydamine hydrochloride (a topical nonsteroidal anti inflammatory drug) gargles for prevention of POST. We enrolled 60 consecutive female patients, 16-60 yr of age, ASA physical status I or II, undergoing elective modified radical mastectomy under general anesthesia in this prospective, randomized, placebo-controlled, single-blind study. Patients were randomly divided into 3 groups of 20 subjects each: Group 1 (C) mineral water; Group 2 (AS) tab aspirin 350 mg; and Group 3 (BH) 15 mL of Benzydamine hydrochloride (0.15%). All the medications were made into 30 mL of solution. Patients were asked to gargle this mixture for 30 s, 5 min before induction of anesthesia. Grading of POST was done at 0, 2, 4, and 24 h postoperatively on a 4-point scale (0-3). Aspirin gargles reduced the incidence of POST for 4 h whereas Benzydamine hydrochloride gargles reduced POST for 24 h. POST was more severe in the control group at 0 and 2 h (P < 0.05). Aspirin and Benzydamine hydrochloride gargles significantly reduced the incidence and severity of POST (P < 0.05).

H Maeda - One of the best experts on this subject based on the ideXlab platform.

  • topical Benzydamine hydrochloride for prevention of postoperative sore throat in adults undergoing tracheal intubation for elective surgery a systematic review and meta analysis
    Anaesthesia, 2018
    Co-Authors: A Kuriyama, M Aga, H Maeda
    Abstract:

    Postoperative sore throat has a negative impact on patient satisfaction and recovery. Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug available for topical use. We performed a systematic review and meta-analysis to assess the efficacy and safety of topical application of Benzydamine to prevent postoperative sore throat in adults undergoing elective surgery under general anaesthesia. We searched PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials to identify relevant randomised controlled trials and pooled the data using a random effects model. The primary outcomes were the incidence and severity of sore throat 24 h after surgery/extubation, and adverse events. The quality of evidence was assessed using the grading of recommendations, assessment, development and evaluation (GRADE) criteria. Thirteen randomised controlled trials involving 1842 patients were included. Compared with control patients who did not receive analgesia, Benzydamine was associated with a decreased incidence of postoperative sore throat, with a risk ratio (95%CI) of 0.31 (0.20-0.47), but not with significantly reduced severity, the standardised mean difference (95%CI) being -0.27 (-0.63 to 0.08). There were no significant adverse events related to Benzydamine. Benzydamine was also associated with a reduced incidence of postoperative sore throat when compared with lidocaine, with a risk ratio (95%CI) of 0.18 (0.07-0.43). We judged the evidence for the outcome 'incidence of postoperative sore throat' as high quality.

Jin Young Hwang - One of the best experts on this subject based on the ideXlab platform.

Mario Pinza - One of the best experts on this subject based on the ideXlab platform.

  • Benzydamine inhibits monocyte migration and mapk activation induced by chemotactic agonists
    British Journal of Pharmacology, 2003
    Co-Authors: Elena Riboldi, Claudio Milanese, Angelo Guglielmotti, Mario Pinza, Giada Frascaroli, Pietro Transidico, Walter Luini, Sergio Bernasconi, Francesca Mancini, Silvano Sozzani
    Abstract:

    1. The present study was aimed to investigate the effect of Benzydamine, an anti-inflammatory drug devoid of activity on arachidonic acid metabolism, on monocyte chemotaxis and to define the possible biochemical correlates of activity. 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a. The effect was dose-dependent with IC50's of 100, 50 and 45 microm for MCP-1/CCL2, fMLP and C5a, respectively. At the dose of 100 microm, the effect resulted in a 50+/-10% inhibition of MCP-1/CCL2-induced chemotaxis and 53+/-6 and 54+/-5% inhibitions of chemotaxis in response of fMLP and C5a, respectively (n=3). 3. Receptor expression as well as calcium fluxes in response to chemoattractants were not affected by Benzydamine. 4. Benzydamine strongly inhibited chemoattractant-induced activation of the mitogen-activated protein kinase (MAPK) ERK1/2, and of its upstream activator kinase MEK1/2. ERK1/12 activation in response to chemoattractants was 89-98% inhibited by a 100 microm concentration of Benzydamine with an IC50 of 30 microm. 5. Under the same experimental conditions, pretreatment with 100 microm Benzydamine caused a 75-89% inhibition of p38 activation (IC50 25 microm). 6. These results indicate that the anti-inflammatory activity of Benzydamine is exerted at multiple levels, including monocyte migration to chemotactic factors associated to a blockage of ERK and p38 MAPK pathways.

  • differential effect of Benzydamine on pro versus anti inflammatory cytokine production lack of inhibition of interleukin 10 and interleukin 1 receptor antagonist
    International Journal of Clinical & Laboratory Research, 2000
    Co-Authors: Marina Sironi, Mario Pinza, Pietro Transidico, Silvano Sozzani, Lucia Massimiliano, Alberto Mantovani, Annunciata Vecchi
    Abstract:

    The production and action of primary proinflammatory cytokines are strictly controlled by a series of circuits to avoid damage that they can cause if produced in excess. Interleukin-10 and interleukin-1 receptor antagonist contribute to the control of the magnitude of the inflammatory responses in vivo. Benzydamine, a non-steroidal anti-inflammatory drug that has been shown to have suppressive activity for the proinflammatory cytokines, tumor necrosis factor-α and interleukin-1β, was investigated for its effects on interleukin-10 and interleukin-1ra production. The drug did not modify the production of interleukin-10 and interleukin-1ra by peripheral blood mononuclear cells stimulated with lipopolysaccharide, under conditions where tumor necrosis factor-α and interleukin-1β were decreased. The antiinflammatory capacity of Benzydamine might thus result from its ability to reduce the production of proinflammatory cytokines, without affecting antiinflammatory factors.

  • Benzydamine protection in a mouse model of endotoxemia
    Inflammation Research, 1997
    Co-Authors: A Guglielmotti, Isabella Coletta, Carla Landolfi, Lucia Soldo, L Aquilini, M T Rosignoli, Mario Pinza
    Abstract:

    Objective: Previous studies have shown that Benzydamine (40 mg/kg s.c.) is able to inhibit tumor necrosis factor (TNF) production and to reduce mouse lethality when administered before or concomitantly with LPS. The present study was designed to further investigate Benzydamine activity against LPS-induced toxicity in terms of potency and therapeutic effects.¶Methods: Female Balb/c mice were used. A dose-response curve of animal lethality versus endotoxin dose was performed (LD50 = 45 μg/mouse). Therapeutic effects were studied selecting the dose of LPS to achieve an LD100 (160 μg/mouse). Mortality was assessed daily and mice were followed for 8 days. The potential mode of action of therapeutically administered Benzydamine was also investigated. TNFα and IL-1β levels were measured, at 5 h after LPS injection, both in sera and in lungs. Moreover, the drug was assayed in a TNF-dependent cytoxicity test.¶Results: Benzydamine, administered at 20 mg/kg s.c. simultaneously with the endotoxin, significantly increased LPS LD50 up to 230 μg/mouse (p < 0.05). Moreover, the drug significantly protected mice against LPS-induced lethality when administered either 30 min or 4 h after endotoxin injection (p < 0.001). Benzydamine, therapeutically administered at 20 mg/kg s.c., significantly reduced TNFα and IL-1β production induced by LPS both in serum and lungs and it was shown to inhibit TNF-dependent cytoxicity on L929 cells.¶Conclusions: These results clearly demonstrate the therapeutic activity of Benzydamine in a simple model of endotoxic shock. Available data confirm the potential role of Benzydamine as an anti-cytokine agent and provide suggestions for novel therapeutic applications of this anti-inflammatory drug.

  • Benzydamine inhibits the release of tumor necrosis factor α and monocyte chemotactic protein 1 by candida albicans stimulated human peripheral blood cells
    International Journal of Clinical & Laboratory Research, 1997
    Co-Authors: Marina Sironi, Claudio Milanese, Annunciata Vecchi, L Polenzani, Angelo Guglielmotti, Isabella Coletta, Carla Landolfi, Lucia Soldo, A Mantovani, Mario Pinza
    Abstract:

    Benzydamine is a non-steroidal antiinflammatory drug, devoid of activity on arachidonic acid metabolism, which is extensively used as a topical drug in inflammatory conditions, particularly for the treatment of bacterial vaginosis andCandida albicans-sustained vaginitis. In the present study the effects of Benzydamine on the production of several inflammatory cytokines were examined in cultures ofCandida albicans-stimulated human mononuclear cells. Benzydamine (6.25-50 ΜM) inhibitedCandida-induced tumor necrosis factor-α and, to a lesser extent, interleukin-1 Β production, whereas it did not affect interleukin-6 release. Benzydamine also blocked monocyte chemotactic protein-1 secretion, but it did not affect interleukin-8 production. Unlike Benzydamine, ibuprofen and naproxen, two non-steroidal antiinflammatory drugs also used topically, were unable to suppress inflammatory lymphokine production fromCandida-activated mononuclear cells. These data suggesrthat Benzydamine may be effective in localCandida infections at least in part by suppressing inflammatory cytokine and monokine production in the vaginal mucosa and consequently decreasing their levels in vaginal secretions.

  • inhibition of inflammatory cytokine production and protection against endotoxin toxicity by Benzydamine
    Cytokine, 1996
    Co-Authors: Marina Sironi, Claudio Milanese, Annunciata Vecchi, Angelo Guglielmotti, Isabella Coletta, P Pozzi, Nadia Polentarutti, Fabio Benigni, Pietro Ghezzi, Mario Pinza
    Abstract:

    The present study was designed to assess the effect of N,N-dimethyl-3-[(1-benzyl-1H-indazol-3-yl)ossi]-1-propana mine (Benzydamine) on in vivo and in vitro production of inflammatory cytokines. Benzydamine inhibited tumour necrosis factor-alpha (TNF-alpha) production in vitro by human lipopolysaccharide-stimulated monocytes with an ED50 of approximately 25 microM (12 donors). Under the same conditions, Benzydamine had modest or no effect on production of interleukin (IL-1), IL-6 and IL-8. Inhibition of TNF-alpha production was not restricted to LPS in that similar results were obtained using inactivated streptococci. Inhibition of TNF production was associated with a modest (about 30% at 50 microM, 7 donors) reduction of mRNA. A similar inhibition of TNF-alpha production was also detected with mouse peritoneal macrophages. With mouse cells Benzydamine also substantially inhibited IL-1 production in vitro. In vivo treatment with Benzydamine (40 mg/kg s.c.) protected mice against LPS lethality. Protection against septic shock was observed when Benzydamine was administered before or concomitantly with LPS. Protection against LPS toxicity was associated with a marked reduction of serum levels of TNF-alpha and IL-1 beta, whereas IL-6 was unaffected. Inhibition of inflammatory cytokine production may play a role in the anti-inflammatory activity of Benzydamine and provide suggestions for novel therapeutic applications.